Department of Radiology, University of Washington School of Medicine, Seattle, United States.
Br J Radiol. 2022 Apr 1;95(1132):20210824. doi: 10.1259/bjr.20210824. Epub 2021 Nov 9.
Positron emission tomography (PET) is a quantitative molecular imaging modality increasingly used to study pulmonary disease processes and drug effects on those processes. The wide range of drugs and other entities that can be radiolabeled to study molecularly targeted processes is a major strength of PET, thus providing a noninvasive approach for obtaining molecular phenotyping information. The use of PET to monitor disease progression and treatment outcomes in DLD has been limited in clinical practice, with most of such applications occurring in the context of research investigations under clinical trials. Given the high costs and failure rates for lung drug development efforts, molecular imaging lung biomarkers are needed not only to aid these efforts but also to improve clinical characterization of these diseases beyond canonical anatomic classifications based on computed tomography. The purpose of this review article is to provide an overview of PET applications in characterizing lung disease, focusing on novel tracers that are in clinical development for DLD molecular phenotyping, and briefly address considerations for accurately quantifying lung PET signals.
正电子发射断层扫描（PET）是一种定量分子成像方式，越来越多地用于研究肺部疾病过程和药物对这些过程的影响。可以放射性标记以研究分子靶向过程的广泛的药物和其他实体是 PET 的主要优势，从而为获得分子表型信息提供了一种非侵入性方法。在 DLD 中，使用 PET 监测疾病进展和治疗结果在临床实践中受到限制，大多数此类应用是在临床试验背景下的研究调查中进行的。鉴于肺部药物开发工作的高成本和失败率，不仅需要分子成像肺部生物标志物来帮助这些工作，还需要超越基于计算机断层扫描的经典解剖分类来改善这些疾病的临床特征。本文的目的是概述 PET 在肺部疾病特征描述中的应用，重点介绍用于 DLD 分子表型的新型示踪剂，并简要讨论准确量化肺部 PET 信号的注意事项。
